<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807144</url>
  </required_header>
  <id_info>
    <org_study_id>ICKTI08TX02</org_study_id>
    <secondary_id>2008-000889-22</secondary_id>
    <nct_id>NCT00807144</nct_id>
  </id_info>
  <brief_title>Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation</brief_title>
  <acronym>TAESR</acronym>
  <official_title>A Phase-IV Study Comparing Standard Release Tacrolimus (Prograf) vs Prolonged-release Tacrolimus (Advagraf) Monotherapy as Maintenance Immunosuppression After Induction With Alemtuzumab in Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College Healthcare NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current anti-rejection drug regime for kidney transplant recipients in use at the West&#xD;
      London Renal &amp; Transplant Centre (WLRaTC) consists of induction therapy with the very potent&#xD;
      monoclonal antibody Campath 1-H (Alemtuzumab) followed by long-term maintenance with the&#xD;
      Calcineurin inhibitor Tacrolimus&#xD;
&#xD;
      The recent development (and licensing in the UK) of an extended-release, once daily&#xD;
      formulation of Tacrolimus holds out the promise of simpler drug regimes for our patients. In&#xD;
      the context of our current successful use of Tacrolimus monotherapy maintenance after Campath&#xD;
      1-H induction, the extended-release Tacrolimus formulation will enable us to offer a regime&#xD;
      where the only long-term immunosuppressive treatment that most of our patients need will be a&#xD;
      single drug, taken once a day.&#xD;
&#xD;
      The investigators wish to assess the efficacy of such a regime in a structured comparison&#xD;
      with our current protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Purpose of Study:&#xD;
&#xD;
           The current immunosuppressive regime used as anti-rejection therapy after kidney&#xD;
           transplantation in the West London Renal &amp; Transplant Centre at Imperial College&#xD;
           Healthcare NHS Trust consists of induction therapy with Campath 1-H(Alemtuzumab) and a 1&#xD;
           week course of steroids followed by maintenance mono-therapy with standard-release&#xD;
           (twice daily) Tacrolimus (Prograf). This study is designed to compare the costs and&#xD;
           outcomes of this regime with one in which extended-release (once daily) Tacrolimus&#xD;
           (Advagraf) is used in place of the standard-release Tacrolimus.&#xD;
&#xD;
        2. Study Type: Phase IV&#xD;
&#xD;
        3. Study Design: Prospective, randomised, controlled, open study. Patients will be&#xD;
           randomized 1:1 between the standard and extended-release Tacrolimus arms.&#xD;
&#xD;
           Study entry will be stratified by live donor vs deceased donor transplants. The total&#xD;
           recruitment target is 100 patients (50 standard release/50 extended release).&#xD;
&#xD;
        4. Study Description:&#xD;
&#xD;
      Patients will be randomised to receive either Prograf or Advagraf prior to transplantation.&#xD;
&#xD;
      Other than through the taking of extra blood samples at the time of routine clinical visits,&#xD;
      participants will receive identical in-patient and out-patient management to patients&#xD;
      undergoing kidney transplantation under our standard protocol.&#xD;
&#xD;
      Patients in the study will be asked to complete a short Health-Related Quality of Life&#xD;
      questionnaire (SF-36) before transplantation and at 1 year post transplant. They will also be&#xD;
      asked to complete a Medication Adherence Rating Score at 3, 6, and 12 months post-transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Survival With a Functioning Graft</measure>
    <time_frame>One year post kidney transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rejection-free Patient Survival With a Functioning Graft</measure>
    <time_frame>One and two years post kidney transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Quality of Life, and Medication Adherence</measure>
    <time_frame>3,6,&amp; 12 months post kidney transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>End-stage Renal Failure</condition>
  <condition>Graft Rejection</condition>
  <arm_group>
    <arm_group_label>Prolonged-Release Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transplant maintenance immunosuppression with Prolonged-release Tacrolimus monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-Release tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transplant maintenance immunosuppression with Standard-release Tacrolimus monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus (Kidney transplant maintenance immunosuppression)</intervention_name>
    <description>Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml</description>
    <arm_group_label>Standard-Release tacrolimus</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kidney transplant maintenance immunosuppression</intervention_name>
    <description>Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml</description>
    <arm_group_label>Prolonged-Release Tacrolimus</arm_group_label>
    <other_name>Advagraf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Live donor kidney transplant recipients&#xD;
&#xD;
          -  heart-beating-Deceased donor kidney transplant recipients&#xD;
&#xD;
          -  Patients suitable for induction therapy with Alemtuzumab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recipients of Non-heart-beating deceased donor kidney transplants&#xD;
&#xD;
          -  Recipients of simultaneous kidney/pancreas transplants&#xD;
&#xD;
          -  ABO incompatible/desensitized transplant recipients&#xD;
&#xD;
          -  Positive flow cross-match/desensitized transplant recipients&#xD;
&#xD;
          -  Patients with heavy prior exposure to myelosuppressive therapy&#xD;
&#xD;
          -  Patients with previous malignancy&#xD;
&#xD;
          -  Patients with HIV,Hepatitis-C, or Hepatitis-B infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam G McLean, MA DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College Kidney &amp; Transplant Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West London Renal &amp; Transplant Centre, Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://atcmeetingabstracts.com/abstract/1-year-outcomes-of-a-prospective-open-label-randomized-controlled-trial-of-standard-vs-extended-release-tacrolimus-as-maintenance-monotherapy-in-kidney-transplantation-after-alemtuzumab-induction-w</url>
    <description>Conference abstract</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 10, 2008</study_first_submitted>
  <study_first_submitted_qc>December 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2008</study_first_posted>
  <results_first_submitted>January 23, 2020</results_first_submitted>
  <results_first_submitted_qc>August 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 27, 2021</results_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney transplant</keyword>
  <keyword>Rejection</keyword>
  <keyword>Adherence</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Extended Release Tacrolimus</title>
          <description>Transplant maintenance immunosuppression with Prolonged-release Tacrolimus monotherapy&#xD;
Kidney transplant maintenance immunosuppression: Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml</description>
        </group>
        <group group_id="P2">
          <title>Standard Release Tacrolimus</title>
          <description>Transplant maintenance immunosuppression with Standard-release Tacrolimus monotherapy&#xD;
Tacrolimus (Kidney transplant maintenance immunosuppression): Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Extended Release Tacrolimus</title>
          <description>Transplant maintenance immunosuppression with Prolonged-release Tacrolimus monotherapy&#xD;
Kidney transplant maintenance immunosuppression: Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml</description>
        </group>
        <group group_id="B2">
          <title>Standard Release Tacrolimus</title>
          <description>Transplant maintenance immunosuppression with Standard-release Tacrolimus monotherapy&#xD;
Tacrolimus (Kidney transplant maintenance immunosuppression): Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.1" spread="15.8"/>
                    <measurement group_id="B2" value="51.5" spread="14.04"/>
                    <measurement group_id="B3" value="52.3" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Afro Carribean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Survival With a Functioning Graft</title>
        <time_frame>One year post kidney transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Extended Release Tacrolimus</title>
            <description>Transplant maintenance immunosuppression with Prolonged-release Tacrolimus monotherapy&#xD;
Kidney transplant maintenance immunosuppression: Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml</description>
          </group>
          <group group_id="O2">
            <title>Standard Release Tacrolimus</title>
            <description>Transplant maintenance immunosuppression with Standard-release Tacrolimus monotherapy&#xD;
Tacrolimus (Kidney transplant maintenance immunosuppression): Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Survival With a Functioning Graft</title>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rejection-free Patient Survival With a Functioning Graft</title>
        <time_frame>One and two years post kidney transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Extended Release Tacrolimus</title>
            <description>Transplant maintenance immunosuppression with Prolonged-release Tacrolimus monotherapy&#xD;
Kidney transplant maintenance immunosuppression: Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml</description>
          </group>
          <group group_id="O2">
            <title>Standard Release Tacrolimus</title>
            <description>Transplant maintenance immunosuppression with Standard-release Tacrolimus monotherapy&#xD;
Tacrolimus (Kidney transplant maintenance immunosuppression): Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Rejection-free Patient Survival With a Functioning Graft</title>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.4"/>
                    <measurement group_id="O2" value="80.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Year 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Year 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient-reported Quality of Life, and Medication Adherence</title>
        <time_frame>3,6,&amp; 12 months post kidney transplant</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Release Tacrolimus</title>
            <description>Transplant maintenance immunosuppression with Prolonged-release Tacrolimus monotherapy&#xD;
Kidney transplant maintenance immunosuppression: Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml</description>
          </group>
          <group group_id="O2">
            <title>Standard Release Tacrolimus</title>
            <description>Transplant maintenance immunosuppression with Standard-release Tacrolimus monotherapy&#xD;
Tacrolimus (Kidney transplant maintenance immunosuppression): Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Patient-reported Quality of Life, and Medication Adherence</title>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Extended Release Tacrolimus</title>
          <description>Transplant maintenance immunosuppression with Prolonged-release Tacrolimus monotherapy&#xD;
Kidney transplant maintenance immunosuppression: Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml</description>
        </group>
        <group group_id="E2">
          <title>Standard Release Tacrolimus</title>
          <description>Transplant maintenance immunosuppression with Standard-release Tacrolimus monotherapy&#xD;
Tacrolimus (Kidney transplant maintenance immunosuppression): Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any rejection symptom</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam McLean</name_or_title>
      <organization>Imperial College Healthcare NHS Trust</organization>
      <phone>+44 020 8383 5164</phone>
      <email>adammclean@nhs.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

